XOMA Corporation (XOMA): Price and Financial Metrics
XOMA Price/Volume Stats
Current price | $24.05 | 52-week high | $26.83 |
Prev. close | $23.34 | 52-week low | $13.48 |
Day low | $23.25 | Volume | 19,800 |
Day high | $24.54 | Avg. volume | 23,093 |
50-day MA | $22.80 | Dividend yield | N/A |
200-day MA | $18.14 | Market Cap | 279.61M |
XOMA Stock Price Chart Interactive Chart >
XOMA POWR Grades
- XOMA scores best on the Growth dimension, with a Growth rank ahead of 70.04% of US stocks.
- XOMA's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- XOMA's current lowest rank is in the Momentum metric (where it is better than 6.62% of US stocks).
XOMA Stock Summary
- The ratio of debt to operating expenses for XOMA CORP is higher than it is for about just 0.22% of US stocks.
- With a year-over-year growth in debt of -100%, XOMA CORP's debt growth rate surpasses merely 0% of about US stocks.
- Revenue growth over the past 12 months for XOMA CORP comes in at -89.11%, a number that bests merely 1.74% of the US stocks we're tracking.
- Stocks that are quantitatively similar to XOMA, based on their financial statements, market capitalization, and price volatility, are SWIM, COOK, FRGE, MEG, and PIXY.
- XOMA's SEC filings can be seen here. And to visit XOMA CORP's official web site, go to www.xoma.com.
XOMA Valuation Summary
- In comparison to the median Healthcare stock, XOMA's price/earnings ratio is 122.64% lower, now standing at -6.6.
- Over the past 243 months, XOMA's EV/EBIT ratio has gone up 7.7.
Below are key valuation metrics over time for XOMA.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
XOMA | 2023-12-29 | 48.2 | 2.0 | -6.6 | -6.7 |
XOMA | 2023-12-28 | 49.3 | 2.1 | -6.8 | -6.9 |
XOMA | 2023-12-27 | 48.7 | 2.0 | -6.7 | -6.8 |
XOMA | 2023-12-26 | 48.8 | 2.0 | -6.7 | -6.8 |
XOMA | 2023-12-22 | 47.9 | 2.0 | -6.6 | -6.7 |
XOMA | 2023-12-21 | 47.1 | 2.0 | -6.5 | -6.5 |
XOMA Growth Metrics
- Its 3 year cash and equivalents growth rate is now at 82.99%.
- Its year over year price growth rate is now at -42.77%.
- The year over year cash and equivalents growth rate now stands at 26.71%.
The table below shows XOMA's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 40.486 | 21.653 | 9.793 |
2022-06-30 | 40.975 | 22.241 | 9.535 |
2022-03-31 | 40.893 | 22.583 | 12.043 |
2021-12-31 | 38.16 | 22.678 | 7.787 |
2021-09-30 | 29.797 | 9.714 | 5.429 |
2021-06-30 | 29.414 | 10.353 | 10.156 |
XOMA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XOMA has a Quality Grade of C, ranking ahead of 66.13% of graded US stocks.
- XOMA's asset turnover comes in at 0.233 -- ranking 184th of 682 Pharmaceutical Products stocks.
- DARE, WINT, and TCON are the stocks whose asset turnover ratios are most correlated with XOMA.
The table below shows XOMA's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.233 | 1 | 0.187 |
2021-06-30 | 0.252 | 1 | 0.254 |
2021-03-31 | 0.277 | 1 | 0.222 |
2020-12-31 | 0.301 | 1 | 0.242 |
2020-09-30 | 0.025 | 1 | -0.219 |
2020-06-30 | 0.116 | 1 | -0.137 |
XOMA Price Target
For more insight on analysts targets of XOMA, see our XOMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $44.67 | Average Broker Recommendation | 1.67 (Moderate Buy) |
XOMA Corporation (XOMA) Company Bio
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.
Latest XOMA News From Around the Web
Below are the latest news stories about XOMA CORP that investors may wish to consider to help them evaluate XOMA as an investment opportunity.
XOMA Declares Quarterly Preferred Stock DividendsEMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B |
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesLow-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recour |
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueReceived $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent |
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has grant |
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gainThe main point of investing for the long term is to make money. But more than that, you probably want to see it rise... |
XOMA Price Returns
1-mo | -3.61% |
3-mo | 30.00% |
6-mo | 70.69% |
1-year | 10.07% |
3-year | -39.88% |
5-year | 94.26% |
YTD | 30.00% |
2023 | 0.54% |
2022 | -11.75% |
2021 | -52.75% |
2020 | 61.65% |
2019 | 115.81% |
Continue Researching XOMA
Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...